Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Polymyalgia Rheumatica

Interventions

BIOLOGICAL: Secukinumab

Sponsor

Novartis Pharmaceuticals